THE PATHS TO A CURE

Alzheimer’s Drug Discovery Foundation

2014 ANNUAL REPORT
The Alzheimer’s Drug Discovery Foundation’s mission is to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s disease.

**BOARD OF GOVERNORS**

**HONORARY CHAIRMAN**
Justice Sandra Day O’Connor

**CO-CHAIRMEN**
Leonard A. Lauder
Ronald S. Lauder

**VICE CHAIRMAN**
Randal Sandler

**BOARD OF OVERSEERS**

**CO-CHAIRMEN**
Sharon T. Sager
Randal Sandler

Robert Appel*
Robert A. Belfer
Nancy Corzine**
Lady Lynn Forester de Rothschild
Bonnie Pfeifer Evans
Melvin R. Goodes
Nancy Goodes
Laurence C. Leeds
Thomas F. McWilliams
Alice Shure
Peter J. Solomon
Sally Susman
Paula Zahn

**EX OFFICIO**
Howard Fillit, MD

**OFFICERS**
Lisa Somar, Assistant Treasurer and Secretary
Kevin Dieterich, Treasurer

* Appointed in 2015
**Past Board President

Carol Seabrook Boulanger
Charles Cangro
Faith Perlmutter Diamond
Mitchell D. Eichen
Allan M. Green, MD, PhD, JD
Christopher Johnson
Elise Gelman Lefkowitz
Philip Lovett
Emilio Matt
Pamela J. Newman
Phebe Farrow Port
John Scully*
Mary Rose Taylor
Alison Zaino
Linda S. Zambelli

* Appointed in 2015
**Past Board President
Dear Friends,

More than 44 million people worldwide suffer from Alzheimer’s disease and related dementias—and there remains no way to cure or even slow the progress of this devastating illness. But there is hope in drug discovery.

The Alzheimer’s Drug Discovery Foundation (ADDF) is supporting scientists around the globe who are investigating novel drugs to prevent, treat and cure Alzheimer’s disease. Thanks to your generous contributions, these researchers are making remarkable progress.

With your continued support, they can take the steps necessary to bring forth a cure for this devastating disease. Together we can and will conquer Alzheimer’s disease.

With our deepest thanks,

LEONARD A. LAUDER
Co-Chairman and Co-Founder

RONALD S. LAUDER
Co-Chairman and Co-Founder
Will the first disease-modifying drug for Alzheimer’s work by minimizing inflammation in the brain? Or will it protect neurons from damage and death? While researchers have a number of promising hypotheses, they do not yet know which Alzheimer’s drug target will ultimately offer the greatest benefit to the largest number of patients.

That’s why we are investing in a diverse portfolio of therapeutic approaches. We feature projects using several of these approaches in this Annual Report. By spreading our funding across a number of potential drug targets, we increase the likelihood of identifying an effective treatment—and ultimately a cure—for Alzheimer’s disease.

*A data represents the Alzheimer’s Drug Discovery Foundation’s investments in 2014.*
Thanks to your continued generosity, the Alzheimer’s Drug Discovery Foundation was able to support a diverse array of Alzheimer’s research in 2014. Over the course of the year, we awarded 35 new grants to scientists who have already made tremendous progress in their search for effective drugs to prevent, treat and cure this devastating disease. In total, our team is actively managing 125 scientific programs.

While our funded investigators share a common goal, they are pursuing different therapeutic strategies. There are many hypotheses for drug discovery in Alzheimer’s disease, and the scientists we support are exploring a multitude of these. Today, most researchers believe that we’ll need more than one drug to tackle Alzheimer’s disease. Like with heart disease—which can require a combination of drugs to lower cholesterol, reduce blood pressure and prevent blood clots—overcoming Alzheimer’s will likely involve a multi-pronged approach to prevention and treatment.

Our research funding is strategically positioned across a diverse portfolio to increase the odds of developing effective treatments for Alzheimer’s. In 2014, our investment choices included:

- More drug discovery and development science than ever before, with $9.6 million in Alzheimer’s drug investments.
- Increased investment in Alzheimer’s clinical trials, recognizing that research in the field is rapidly advancing and that the need to test new drugs in humans is urgent.
- More funding for clinical trials of existing and approved drugs through repurposing, which can reach patients more quickly and at a lower cost.
- Increased investment in innovative, entrepreneurial biotechnology companies.
- Development of critical educational and networking resources for researchers, ensuring that they have the tools and partners they need to share ideas, contract work and further their expertise.
- Launch of Cognitive Vitality, an online resource that empowers people to protect their aging brain.

In this Annual Report, you will learn even more about the groundbreaking research your generous donations make possible. Your investment in the ADDF and our network of dedicated scientists means that the 44 million people worldwide living with Alzheimer’s and the millions more who love them have hope.

As always, thank you for the privilege of working with you to accelerate the development of effective drugs for Alzheimer’s disease.

Sincerely,

Howard Fillit, MD
Founding Executive Director and Chief Science Officer

LETTER FROM HOWARD FILLIT, MD
Founding Executive Director and Chief Science Officer

DEAR FRIENDS,
In a lab in northern England, Dr. Christian Holscher unpacks new laboratory equipment and carefully inspects the pieces. Dr. Holscher and his team, who are based at Lancaster University, are preparing to investigate whether two experimental diabetes drugs could help prevent the onset of Alzheimer’s disease. If the results of their trial are successful, the most promising of these repurposed drugs could be available to patients with Alzheimer’s disease in the next three to five years.

Dr. Holscher is one of 35 grantees working in Europe, the U.S., and Canada, who received funding from the Alzheimer’s Drug Discovery Foundation in 2014. These researchers—whose projects were vetted by panels of leading experts in Alzheimer’s drug discovery and development—represent some of the best and brightest scientific minds in the world.

In the pages that follow, we’ll introduce you to some of our grantees and the research projects they are driving forward. You can rest assured knowing that these leading Alzheimer’s scientists are doing everything in their power to end this devastating disease—work that would be impossible without your ongoing support.
“It’s impossible to travel in life and not meet people who have a family story to tell about Alzheimer’s.”

Martin Jefson, PhD, says of his work in Alzheimer’s research, “I find it fascinating for all the reasons that most people do. It’s a disorder with a high unmet need. It’s a disease with high economic, social and familial costs.”

But he’s also intrigued by Alzheimer’s for purely scientific reasons. “It’s an absorbing and challenging scientific problem,” Dr. Jefson says. “It’s a classical drug discovery and development opportunity. That is my training and my passion.”

Dr. Jefson is using that training to test the safety and usefulness of a new treatment for Alzheimer’s disease in animal models. The drug, designed to improve brain function and cognition, works through epigenetic mechanisms. It’s a pioneering approach to treating Alzheimer’s, affecting changes in brain function by modifying gene expression and protein levels.

“Funding from the Alzheimer’s Drug Discovery Foundation has been critical to our work,” Dr. Jefson says. “It allowed us to transition from in vitro studies to animal experiments.”

There are currently no other drugs under study to treat cognitive impairment that work through epigenetic mechanisms. It’s not entirely uncharted territory, however. There are now drugs for cancer and other diseases that work similarly.

**NEUROPROTECTION**

As Alzheimer’s disease progresses, neurons (or nerve cells) lose their connections and begin to die, causing the loss of memory and other essential cognitive functions. Scientists are exploring “neuroprotective” treatment strategies to shield nerve cells from damage and death.
After more than three decades in Alzheimer’s research, it’s safe to say that Bradley Hyman, MD, PhD, has a wealth of experience in Alzheimer’s drug discovery. He’s equally well-versed in patient care, something that deeply informs his work in the lab. “I regularly see patients with this tragic illness,” he says. “We need to help now.”

Dr. Hyman is investigating APOE2 gene therapy for Alzheimer’s disease. People with the APOE4 gene have the highest risk of developing Alzheimer’s disease, while those with the APOE2 gene have a decreased risk. Gene therapy would use APOE2 as a treatment for people with the high-risk APOE4 gene. “We have an idea of how to take advantage of information about the genetics of Alzheimer’s disease and a protective gene—APOE2—and turn that knowledge into a way to help patients,” says Dr. Hyman. Research has already demonstrated that treating mice with APOE2 gene therapy can suppress the development of amyloid plaques characteristic of Alzheimer’s disease.

With funding from the Alzheimer’s Drug Discovery Foundation, Dr. Hyman and his team are evaluating the safety and therapeutic benefit of two different APOE2 viral vector approaches. “The ADDF has helped enormously,” he says. “Our research is a little futuristic, and it is fantastic that the ADDF is supporting research like this.”
You might be surprised to hear that Michela Gallagher, PhD, is on sabbatical. So what is she doing with all of her “free” time? She’s buckling down in the lab at AgeneBio in preparation for a Phase 3 trial of AGB101, a new treatment for early-stage Alzheimer’s disease. Its work that she says wouldn’t be possible without the Alzheimer’s Drug Discovery Foundation’s initial support in 2010.

“I don’t know how we would have gotten started at AgeneBio without the ADDF,” Dr. Gallagher says. “It was the bridge to a program that is still doing very well, and we’re tremendously grateful to the Foundation for its continued support.”

The ADDF has been unyielding in its enthusiasm for Dr. Gallagher’s work, most recently investing $900,000 to enable preparations for AgeneBio’s upcoming Phase 3 trial of AGB101. The study will test the drug in patients with amnestic mild cognitive impairment (aMCI), the pre-dementia phase of Alzheimer’s disease in which memory is worse than expected for a person’s age. Most aMCI patients progress to Alzheimer’s dementia within 7 to 10 years.

AGB101 is a proprietary formulation of low-dose levetiracetam, an FDA-approved treatment for epilepsy. In the upcoming study, patients with aMCI will receive just one-twelfth of the regularly prescribed dose of the drug given once a day.

Dr. Gallagher is hopeful that, if results are positive, AGB101 will be available to patients soon after. “It has the advantage of a relatively fast clinical pathway because the safety of the drug is known, and allows us to focus on demonstrating the potential for AGB101 to slow progression of aMCI and delay onset of Alzheimer’s dementia,” she says.

“COGNITIVE ENHANCING

Alzheimer’s disease is characterized by the loss of memory, abstract thinking and judgment, language and other cognitive deficits. Scientists are investigating cognitive enhancing drugs that improve cognitive performance, including memory, problem solving and daily function.
Chronic inflammation in the brain can accelerate Alzheimer’s disease and may be a trigger of the disease. Scientists are investigating drugs that protect against disease- and injury-induced inflammation while preserving normal inflammatory responses.

Thota Ganesh, PhD
Emory University

Thota Ganesh, PhD, believes Alzheimer’s researchers need to shift their attention. “The majority of drug discovery efforts are based on only one hypothesis—that an effective Alzheimer’s drug must target amyloid plaques. We need to focus on testing new hypotheses,” he says.

Dr. Ganesh, an Alzheimer’s researcher and assistant professor of pharmacology, is working on neuroinflammation. “The goal of my research is to find a compound that targets the EP2 receptor [which appears to drive inflammation in Alzheimer’s disease] and works as an anti-inflammatory and neuroprotective agent on patients,” he explains.

With funding from the ADDF, Dr. Ganesh is in the early stages of testing one of his leading drug candidates in animal models. If this preclinical trial is successful, he and the team at Emory University will begin to develop a clinically useful drug for humans.

Paolo Pevarello, PhD
Axxam SPA

Paolo Pevarello, PhD, knows what Alzheimer’s can do to families and caregivers. He’s experienced the effects of the devastating disease within his own family. But as the principal investigator of Axxam SpA, an Italian biotechnology company, Dr. Pevarello is also uniquely positioned to fight it.

With continued support from the Alzheimer’s Drug Discovery Foundation, Dr. Pevarello is making tremendous strides on that front. Since 2011, the ADDF has awarded Axxam three grants to further the company’s research to identify drugs that selectively block the purinergic receptor, P2X7, which is involved in inflammation in the brain.

“In the last five years, there has been an increasing appreciation of the role that neuroinflammation plays in Alzheimer’s disease,” Dr. Pevarello explains. “The P2X7 receptor is pathologically over-activated with Alzheimer’s.”

That’s why Dr. Pevarello is investigating drugs that selectively block the receptor and may be able to minimize brain inflammation. It’s an area of research that, by and large, has remained largely unexplored.

Dr. Pevarello and the Axxam team are currently optimizing leading drug candidates. As he explains, “We’re close to providing a proof-of-concept for our leading drug candidates, which will allow progression through the preclinical path to a clinical candidate.”

Ultimately, Dr. Pevarello hopes that one of his drugs will be part of the solution to the Alzheimer’s crisis. “Alzheimer’s disease is a complex pathology and it’s hard to think that a single ‘magic bullet’ will resolve it,” he says. “Combining two or more complementary approaches, which are currently under evaluation, may speed up the pace toward its cure.”
All cells need energy to maintain healthy function, and brain cells are among the highest energy users. Because energy inefficiency and loss in neurons is a hallmark of Alzheimer’s disease, scientists are working to develop drugs that enhance the function of the energy powerhouses of cells, known as mitochondria.

ENERGY UTILIZATION

What if a treatment for Alzheimer’s disease was already in your medicine cabinet? If Gary Gibson, PhD, is right about his drug—which is a close cousin to vitamin B1 (also known as thiamine)—that might not be far from the truth.

Dr. Gibson’s compound, benfotiamine, works by raising and maintaining thiamine levels. Developed in Japan just after World War II, benfotiamine is more effective than traditional vitamin B1 supplements at increasing thiamine levels.

All patients with Alzheimer’s experience a reduction in their glucose metabolism, a process that is dependent on vitamin B1. Dr. Gibson believes thiamine therapy may “have a large impact on Alzheimer’s disease.”

The evidence for his hypothesis is mounting. Benfotiamine has already proven effective in animal models of Alzheimer’s disease and safe in a double-blind clinical trial in Germany.

Next up: a Phase 2 clinical trial of benfotiamine in patients with early-stage Alzheimer’s disease funded by a partnership between the Alzheimer’s Drug Discovery Foundation, Burke Rehabilitation Hospital and the National Institutes of Health (NIH).

If the results of this study are promising, the formulation—which is already being manufactured by a safe and well-regarded facility in Canada—could be available to patients rapidly.
HOW WE’RE DIFFERENT

The ADDF is the only venture philanthropy focused on funding drug discovery. The path to a cure for Alzheimer’s starts with basic science into how the disease works. This information helps create tests to diagnose and assess Alzheimer’s and gives us the targets for drug discovery and development to treat and cure the disease.

% FUNDING BY AREA

- **Drug Discovery, Development & Clinical Trials**
  Finding a cure

- **Molecular Pathogenesis**
  How the disease works

- **Diagnosis & Assessment**
  How to test for the disease and its progress

- **Epidemiology**
  Describing the impact of the disease on distinct populations

- **Care & Support**
  How the disease affects patients, caregivers and society

*2012–2014 data from The International Alzheimer’s Disease Research Portfolio, a database developed through a collaboration between the National Institute on Aging, which is part of the NIH and the Alzheimer’s Association.*
PARTNERS IN THE DEVELOPMENT OF A CURE

The Alzheimer’s Drug Discovery Foundation puts a premium on partnerships. And we’re proud to work with more than a dozen foundations, businesses and government entities worldwide, including our newest partner, the Harrington Discovery Institute.

Over 10 years ago, we began a relationship with the Association for Frontotemporal Degeneration (AFTD), one of our closest allies in the fight against Alzheimer’s. After a decade of collaboration, the ADDF and the AFTD have jointly funded 24 unique drug discovery programs through grants totaling over $2.7 million. In 2014, the AFTD and the ADDF awarded new grants to Charlotte Teunissen, PhD, VU University Medical Center Amsterdam, and Matthew Disney, PhD, of Scripps Research Institute. Dr. Teunissen is tackling one of the greatest challenges facing frontotemporal degeneration research—differentiating the two most common subtypes of the disease in patients. Dr. Disney is working to design a drug-like compound that prevents a toxic chain of events caused by a genetic mutation, C9ORF72, which is responsible for the majority of familial cases of FTD and ALS.

“We’re very proud of our long-standing collaboration with the ADDF,” says Susan Dickinson, Founding Executive Director, AFTD. “By combining our resources, we have provided the scientific community with a deeper understanding of this understudied disease and given patients and caregivers hope for potential treatments.” Nadine Tatton, PhD, Scientific Director, AFTD, adds, “This is really cutting-edge science, and I believe that we’re supporting truly innovative approaches to drug discovery for Alzheimer’s, FTD and related diseases.”

The ADDF values all of our 2014 partners. We know that when we team up with other forward-thinking organizations, we increase our funding power and our collective expertise—ultimately ensuring that we find a cure for Alzheimer’s and related dementias faster.
From fashion shows to science symposia, the Alzheimer's Drug Discovery Foundation's 2014 lineup of special events made one thing clear: there is hope on the horizon. Throughout the year, more than 1,000 ADDF supporters came together for 13 events that together raised more than $5 million. Our allies gathered to learn more about Alzheimer’s research, meet people grappling with Alzheimer’s, honor advocates and scientists working toward a cure … and celebrate our progress!
Andrew Carnegie famously said, “The man who dies rich, dies disgraced.” Robert J. Appel is guided by this same spirit of philanthropy. Mr. Appel explains, “It’s not just about giving back, but about being active and involved.”

Mr. Appel, who joined the ADDF’s Board in 2015, is a leader in supporting medical research. He chaired his alma mater Cornell University’s immensely successful campaign for Weill Cornell Medical College. And he and his wife recently established the Helen & Robert Appel Alzheimer’s Disease Research Institute there. Though the disease hasn’t affected their family, the Appels have lost close friends to Alzheimer’s. He chose to get involved with the ADDF because: “The problem is complex, and the solution is going to come from research into new drugs. We have to approach the search for a cure from as many ways as we can.”

Mr. Appel’s charitable endeavors go beyond medicine. His love of early American music led him to become Chairman of the Board of Jazz at Lincoln Center. He also serves as Trustee Emeritus and Presidential Councillor for Cornell University. His generosity and hard work in support of nonprofit organizations is a wonderful example of the power of philanthropy.
THANK YOU FOR MAKING IT ALL POSSIBLE!

We are deeply grateful to all those who supported our work in 2014. Your generosity gives us hope for a future without Alzheimer’s disease.

$500,000 and above
Nancy and Melvin R. Goodes
Intra-Cellular Therapies, Inc.
Leslie and Roslyn Goldstein Foundation
Prana Biotechnology Limited
Robert A. and Renée E. Belfer Family Foundation

$100,000 to $499,999
Alzheimer’s Society of UK
Helen and Robert J. Appel
The Association for Frontotemporal Degeneration
The Charles Evans Foundation
Katherine B. and Michael I. Colby
The Estée Lauder Companies Inc.
Julie and Philip H. Geier
The Lauder Foundation
Jo Carole and Ronald Lauder

Elise and Marc D. Lefkowitz
Georgia Melenikiotou-Garinois and Philippe Garinois
Ray and Dagmar Dolby Family Fund
Liz and Randal B. Sandler
Sotheby’s

$50,000 to $99,999
A.P. Kirby, Jr. Foundation, Inc.
Cynthia Breen and Laurie A. Dowley
Paddy Ann and Latham Burns
Nancy Corzine
Nancy and Steven Crown
The David A. and Mildred H. Morse Charitable Trust
Evelyn and Lynn de Rothschild
Anne B. and Joel S. Ehrenkranz
Bruce S. Gelb
Judy Glickman Lauder
Laura and Gary Lauder

William P. Lauder
Bonnie Englehardt Lautenberg
Dalia and Laurence C. Leeds
Dan Lufkin, The Peter Jay Sharp Foundation
National Institutes of Health
Lois Robbins and Andrew Zaro
Betsy and William F. Ruprecht
Nathan E. Saint-Amand
Susan and Peter J. Solomon
Joan Sutton Straus
Carol and Michael Weisman

$25,000 to $49,999
Toby and Ronald A. Altman
Carol Seabrook Boulanger
Rose Marie Bravo and William Jackey
Zoe and William D. Budinger
Melanie and Louis Caceres
Caryn J. Clayman
Michael T. Cohen
Condé Nast Publications
Cures Within Reach
Donnelly Mechanical
Annette and Mitchell D. Eichen
Ernst & Young, LLP
Marilyn and Sam Fox
Dina Merrill Hartley and Ted Hartley
Susan and Roger Hertog

Ronnie F. Heyman
David H. Komansky
Lilly USA, LLC
Beatrice Liu and Philip H. Lovett
Susan Lloyd
Macy’s and Bloomingdale’s
William E. Mayer
Merck Research Laboratories
Shelah and Marc Moller
Neurotrax Corporation
The Northern Trust Company
Nucor Construction
Thomas Pheasant
The Ralph and Ricky Lauren Family Foundation, Inc.
Trish and Steven J. Shapiro
Staples Advantage
Teauman and Grace Fuite Foundation
Tishman Speyer Properties, LP
US Trust, Bank of America Private Wealth Management
Paula Zahn
Alison and Buzz Zaino

$10,000 to $24,999
Pennie and Gary Abramson
Jennifer and Claude Amadeo
Judy and John M. Angelo
Placido Arango
Howard Fillit, MD
Kate Ford and Frank Chopin
Georgia and Ronald L. Frasch
Mary Ann and Fabrizio Freda
Carolee Friedlander
Lacy and Ernie Fyrwald
Veronique Gabai-Pinsky
Maria T. Galeno
Genentech USA
Alma L. and Joseph B. Gildenhorn
Sondra Gilman and Celso Gonzalez-Falla
Beth O. and James Kenneth Glassman
Mildred and Arne Glimcher
David Goodes
Jane Mack Gould
Lynne Greene
Laurie B. and Philip M. Gross
Audrey and Martin D. Gruss
Agnes Gund
Sharon Handler and John L. Loeb
James E. Hanson
Jacqueline and Daniel G. Harman
Jane Harman
Harman Family Foundation
Chris Harris
John Hart
Vivien and Alan G. Hassenfeld
Shirley and Barnett Helzberg
Michele and Lawrence Herbert
Catherine J. Hirsch
Agnes Hsu-Tang and Oscar L. Tang
Ann Marie Huebner and Ross P. Waller
Denise M. and John J. Hyland
IDSC
InterVivo Solutions Inc
IRBM
Judith Jackson and Bruce D. Haims
Jill Heller Fine Jewelry Corporation
Cindy Jones
Margaret T. and Bolton Jones
Vernon E. Jordan
Judy & Howard Berkowitz Foundation
Kasper
Mariana and George S. Kaufman
Karen A. and Kevin W. Kennedy
Janet W. Ketcham
Zoe and Shaker Khayatt
Karyn A. Khoury and Stephen Kopach
Phyllis L. Kim
Sidney Kimmel
Diana and Israel Kogan
Michele and Kevah Konner
Deborah and Peter Krulewitch
Carol H. Launer
The Laura Steinberg Tisch Foundation, Inc.
Laurie M. Tisch Illumination Fund
Gretchen and Howard H. Leach
Karen and Richard S. LeFrak
Susan Lehrman
Thelma and Melvin Lenkin
Pierre Levai
Toby Lewis
Peter B. Lichtenthal
Serena and John Liew
Susan and Martin Lipton
Leonard D. Litwin
Carol L. and Eugene A. Ludwig
William Mack
Sandra Main
Dobra and Bennett Marshall
Alison McCall and Peter Elie
McGraw Hill Financial
Joanie and Andrew McKenna
Robin R. and Dennis McNeill
Anita J.H. and Sam Michaels
Elaine and William A. Miller
Sheila and James N. Mills
Fern and Alfred H. Moses
Linda and Sidney Moskowitz
Charlotte Moss and Barry Friedberg
Sara Moss and Michael Gould
Anne W. and Charles Mott
Mulé Family Foundation
Brooke and Daniel M. Neidich
Neiman Marcus Group, Inc.
Newport Painting & Decorating
New York Stem Cell Foundation, Inc.
Melanie and Lawrence Nussdorf
Oryzon
Lisa L. and Mehmet C. Oz
Alex Papachristidis
Partners Healthcare
Susan and Alan J. Patricof
Josie Patton
Elizabeth and Jeffrey M. Peek
Sharon Percy and John D. Rockefeller
Karen and Brian Perlman
Marsha Perreault
Cynthia Hazen Polsky
Laura H. and John Pomerantz
Alma and Colin L. Powell
PsychoGenics, Inc.
QPS
Liam Ratcliffe
Clayton S. Reynolds
Karen and Lewis Rice
Ricerca Bioscience
Sheila Johnson Robbins
Aviva and Jack A. Robinson
Paula and Leon Root
Susan and Elihu Rose
Nancy and Miles Rubin
Kevin M. Ryan
Eric Hangen
Harrington Discovery Institute/Biomotiv
Ellen R. Harris
Elizabeth Hefferon
Pamela Henes
Ken C. Hicks
Diane Hockstader
Richard Hoffman
John Holland
Richard Holub
Cathy and Walter Isaacson
Judy and Verne G. Istock
Rosalind G. Jacobs
David Jacobson
Jill’s Cookie Cart LLC
Marissa T. Johnson
Violeta Jordan
Jayne T. Keith
Victoria E. and Patrick C. Kelly
Eileen and John Kim
Nancy Kistner
David Kossor
John Kossow
Elizabeth S. Kujawski and Tom Zoufaly
Eileen and Richard W. Kunes
Dana Landow
Amy B. and David Liebowitz
Charlotte and Morvin Leibowitz
Pierre Lestage
Lawrence Luebcke
Linda and Harry Macklowe
Hildegard Mahoney
Marlene and Frederic V. Malek
Ekaterini Malliou
Susan Malloy
Ellen Marks
Shirley Maytag-King
Melody McDonough
Lyn and Mark McFadden
Paige and Bart McFadden
Ann McLaughlin and Thomas C. Korologos
Richard Meier
Jennifer and Brad J. Melvin
William O. Melvin
S. Epatha Merkerson
Paul Metselaar
Judith L. Mogul
Robert Morrison
Enid and Lester S. Morse
David Moscow
Jamie Mullen
Bettye Musham
Neiman Marcus Mazza Gallerie
Ellen Newman
William Newsome
Jun Nishiu
Ann K. and William Albert Nitze
Vita Pagnani
Hannah Pakula
Courtney Pastrick
Allison Perlmutter
Jacqueline L. Pletcher
Shilpi Prasad
Inez N. Richardson
Molly Robb
Anne Rojas
Shirley Lord Rosenthal
Sarah Rothman
Adam Rowe
Connie and Peter Ruben
Sara A. and Paul S. Russell
Lisa and Sal Salibello
Ellin Jane Saltzman
Evelyn Sandground and Bill Perkins
Frances G. Scaife and Tom McCarter
Edith F. and Gerald H. Schaeffer
Nancy Seltzer
Leslie Shapiro
Robyn Shepherd and Alex Drolet
Shirley S. and Albert H. Small
Lisa and Denis Somar
George A. Sorial
Jill Gloria Spalding
Stephanie Spinola
Bonnie Staffier
Linda Stargatt and Lawrence P. Mann
Sue and Michael Steinberg
Margaret Stouffer
Bonnie and Thomas W. Strauss
T. Rowe Price Foundation, Inc.
Vicki and Harold Tananbaum
Karen Tandy
Neil Thompson
Judith and Michael Thoyer
Annie S. Totah
Truist
United Way of Greater Toronto
Sahba Vaziri and Ali Reza
Irene E. and Lawrence Waxman
Marcia and Robert Waxman
Molly and Peter Weinberger
Christie Weiner
Constance C. and Arthur C. Weisenseel
Andrea Weiswasser
Westminster Canterbury
Carol and Michael Winer
Michael Wolfson
Helena Wong

$250 to $499
Benedict Albensi
Jane and David Atkins
Martin Auerbach
René Augustine and Mark Alarie
John Avery
AWA Family Foundation
Susan and Joel Bell
Sarah Bendit
Andrew M. Blum
Justin Boyd
Karen and Mitchell Brand
BrightFocus Foundation
Brighton Jones, LLC
Lori H. Bubes
Nancy and Alan Bubes
Nora Burke
Joanne Butler
Nigel Cairns
Hilary P. and Joseph A. Califano
CanadaHelps
Susan Chapman
Alina Cho
Judith G. Churchill
Joy W. and S. Robert Cohen
Robert Colacello
Paul Coleman
Robyn and William M. Collins
Carol A. Colton
Joanne Contopoulos
David Corbin
Michael J. Corcoran
Linda V. Courie
Maria Crowley
Lisa B. Crupi
Mary H. and Myron P. Curzan
Maureen Dalton
Dattner Architects
Corinne Davidov
Eliot Davidowitz
Sandi A. Davidson
Barbara and Ronald Demczak
John Didsbury
Joyce and David N. Dinkins
Jamie Dorros
Silvia and Peter Dreyfuss
Barbara Eager
Diana and Stephen Elkin
Susan Emanuel
Shane Evans
Marjorie Everitt
Joseph Farley
Jose Fernandez
Kathryn Fleischer
Linda N. and Jay Weil Freedman
Helen Freifeld

Laurie Friedman
Marisa L. and Ross S. Friedman
Anders Fugelli
Scott H. Gamber
Darby E. and J. Montgomery Gingery
Susan Goldberg
Barbara and Robert Goldfarb
Geoff Golding
Goldman Sachs & Co. Matching Gifts Program
Jane and Richard D. Grant
Mark Gurney
Jennifer Haber
PengCheng Han
Lori and Khaled T. Haram
Madelyn C. Harris
Alexandra Hartenbaum
Melissa Hawks
Susan C. and Robert M. Hayes
Joan L. Hayman
Jody and Andy Hecht
Janne Heifetz
Linda and Dennis A. Herman
Robert M. Higdon
Robert Hillman
Beth A. Hollister
Kristin Huber
Raeanne Hytone
Ira M. Resnick Foundation, Inc.

Catherine Jackson
Lisa Jobe
Lady Barbara Thomas Judge
Amal Kaddoumi
Nancy Katz
David Kemp
Anne and Robert Kiely
Kevin Kitt
Carol Klein
Carol and B. Erik Knudsen
Peter O. Lawson-Johnston
Valerie Lederberg
Marie and Leighton Lee
Mary Joe Lent and Juan Salgado
Daniel Levesque
Barbara and Harvey Levinson
Wencheng Liu
Stacey and Greg Lubar
Joyce F. Luchtenberg
Elizabeth H. LuFkin
Patricia Lunke and Gary Lunke
Gladys Maestre
Carolyn B. Maloney
Suzanne and Michael M. Maney
Vivien K. Marion
Kathleen and Chris Matthews
Wendy and Daniel McGrath
Laura McIntire
Alan M. Mendelson
Mary Louise and Elias K. Michaelis
Jacqueline Michel and David Weissman
Catherine Miller, College of Law
Jennifer Miller and Mark Ehret
Virginia A. Millhiser
John Millyard
Judy Minor
Liat Mintz
Triana M. and James Moe
Judith L. and Mark Morris
Julie and William Obering
Deb O’Hara-Rusckowski
John Osth
Steven Padgett
Koula K. and Thomas N. Papadopoulos
Jack Pasini
Louise and Paul Pesale
Suzana Petanceska
Fizer Foundation Matching Gifts Program
Mir Polacheck
Diane and Edward A. Powell
Teddy Puschkarski
Jay Radin
Leslie and J. Andrew Rahl
Katherine L. and Edward J. Railey
Ashish Raj
Chongzhao Ran
Natalie Rasgon
Larry Refolo
Dorothy Elizabeth Reifenheiser
David Resnicow, Resnicow Schroeder Associates, Inc.
Nancy F. and Gary N. Reynolds
Diego Rincon-Limas
Robert Dector Associates
Lexi Rodriguez
Janet Rogozinski
Stacey Rosenthal
Kay Sadeghian
Saks Fifth Avenue
Hasib Salah-Uddin
Rosita Sarnoff
Sandra L. and Lowell F. Satler
Susan and Gerald S. Savitsky
Pat Schoenfeld
John Seabrook
Alan D. Seget
Jul Lea Shamy
Paul Sherrill
Nayun Shin
Lauren Shortt
Lois Siegel
Deborah Sigmund
Patricia Silver
Marla and Thomas Sinchak
Carol and David Sinclair
Ambuj Singh
Andre Spearman
William Squier
Martine and James A. Stamos
Stephen M. Stay
Maxwell Stock
Benita Stokes
Joan A. Stone
Leslye and Fred Sugar
Patti Sullivan
John S.M. Svendsen
Francesca Tedesco
RJ Tesi
Bradley Thayer
Julia Tolkan
Theodore Torphy
Caroline and Albert H. Turkus
University of Maryland Athletics
Vasiliki and John L. Valanos
Mike Vitek, PhD
Molly Wagster
Loretta and Charles F. Walz
I-Fan Wang
Deb and Bernie Weiss
Elizabeth and Walter Welsh
Allicia Wertheim
Tina West, MD
Martin Williams
Manfred Windisch
Paula and Alan Wiseman
Eric Wittenberg
Stephanie and Christian Wollny
Joseph Yurcik
Laura and Shariar Zaimi
Yvonne Zoomers

In Kind Gifts
Abrielle Fine Linens and Lingerie, Inc.
Tina Alster, MD
Amaryllis, Inc.
Balance, Your Pilates, Yoga & Gyrotonic Studio
Rochelle and Bernard Bloom
Bobbi Brown Cosmetics
Bumble and bumble.
Café Milano
Chelsea Piers
Colliers International NYC LLC
Stacey Cooper
Nancy Corzine
Daniel
dell'anima
Dempsey & Carroll
Design Cuisine
Allison Diener Perlmutter at Deiner Jewelers
elan Indique
The Estée Lauder Companies Inc.
Fiola da Fabio Trabocchi
First Republic Bank
Four Seasons Hotel Washington, DC
Fourth Wall Restaurants LLC
Gillies Coffee Company, Brooklyn
New York
Anya Hindmarch
Jenny Ng Designs
Jill’s Cookie Cart LLC
JRINK JUICERY
Dorothy Bush Koch
Kurent Events Catering
Linda Landaw
Elise and Marc Lefkowitz
The Mayflower Grace
Metrokane—a Division of Taylor
Precision Products
Michael’s Restaurant New York
NBCUniversal
Thomas Pheasant
The Phillips Collection
Prestige Beverage Group
Rasika West End
The Ritz-Carlton New York, Central Park
The Ritz-Carlton, Washington, DC
Robin Labb Jewelry
Sharon T. Sager
Saks Fifth Avenue
Sirio Ristorante
The Spa at the Peninsula New York
Stoli Group USA
Teuscher Chocolates of Switzerland
Andrew Turk
Washington Nationals
Tina West, MD / The West Institute
Warby Parker
Wölffer Estate Vineyards

IN MEMORY

We remember all those taken by Alzheimer’s in 2014 by continuing to fight for a cure.

Margaret Louise Ashburner
Jacques Boulanger
Marie Hunan Brennan
Edward Carney
Melvin R. Clayman
Betty King Culbreath-Gibbons
Willis Denekas
Louis DiPasquale
Lev Dobrovinskiiy
Russell Eugene Edwards
Bernice Elkin
William M. English
Beatrice Fey
Jonathan E. Franzblau
Leon Gilbert
James Grant
Marilyn Harvey
Marilyn Harvey
Sally Hokanson
Luisa Juncosa
Joanne Ladd
Chauncey Lufkin, Jr.
Jack Mausner
Charles Minichiello
Eloise Mondau
Jose A. Nessim
Mary Maughan Patton
Esta L. Poole
VS Ramalingam
Doris Ray
Dorothy Willison Reed
Rebecca Ritchie
Ron Schick
Rosina Silla
Evelyn Singer
Gertrude Sokol
Sonny Spears
Amelia Ubinas
Francis J. Webb
In 2014, many generous gifts were made to the Alzheimer’s Drug Discovery Foundation in honor of friends and loved ones.

Jessie Agosto
Sharon Anderson
Shelley Banks
Jerald Barnett
Isabelle Black
Rochelle and Bernard Bloom
Faith Bobrow
Carol Boulanger
James Lewis Bragg
Jean Brigati
Ben Burke
Eileen Caprio
I-Ling Chow
Phyllis Coffin
Antonio Coppola
Amiee Darling
Albert Dvorkin
Betty Farrell
Howard Fillit, MD
Sue Finnell

Irene Friedman
Abraham Gelber
Maria Giannissis
Phyllis Gingery and Ruth Brateng
Nancy and Melvin R. Goodes
Louis James Goodman
Robert Gotkin
Carol Gruber
Flora Guglielmino
Chelsea Guida and John Temm
Frank and Theresa Hargrave
Pauline Harris
Christopher Johnson
Susan Katze
Sophia Kay
Betty Keegan
Rachel Lane
Leonard A. Lauder
Laurence Leeds
Vivienne Malba

Elaine and Bill Miller
Nancy Corzine Interiors
S.I. Newhouse
Dorothy Oliverio
Eileen Palevsky
Richard Pearman
Rasika West End
Dolly Reed
Phoebe Rice
Jacqui Rosshandler and
Matthew Dicker
Janice Rudbart
Polly Runyon
Sharon Sager
Jackie Sandler
Randal Sandler
Jeannine Bouiller Siegmond
B. Smith
Joan Sutton Straus
Joan Taylor

Amelia Ubinar
Jordan Via
Mollie Wein
Lenny Witowski
Mike and Grace Yalich
The Yuengling Family
2014 FINANCIAL OVERVIEW

STATEMENT OF FINANCIAL POSITION

<table>
<thead>
<tr>
<th>ASSETS 12/31/14</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td></td>
</tr>
<tr>
<td>Operating</td>
<td>$ 4,633,217</td>
</tr>
<tr>
<td>Restricted</td>
<td>274,468</td>
</tr>
<tr>
<td>Cash held by related party</td>
<td>15,640</td>
</tr>
<tr>
<td>Total cash and cash equivalents</td>
<td>4,923,325</td>
</tr>
<tr>
<td>Investments, at fair value</td>
<td>10,809,963</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>4,059,717</td>
</tr>
<tr>
<td>Due from Institute for the Study of Aging</td>
<td>133,215</td>
</tr>
<tr>
<td>Other assets</td>
<td>26,103</td>
</tr>
<tr>
<td>Total assets</td>
<td>$ 19,952,323</td>
</tr>
</tbody>
</table>

LIABILITIES AND NET ASSETS

<table>
<thead>
<tr>
<th>Liabilities</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued liabilities</td>
<td>$ 49,324</td>
</tr>
<tr>
<td>Grants payable</td>
<td>11,513,136</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>61,350</td>
</tr>
<tr>
<td>Total liabilities</td>
<td>11,623,810</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Net assets</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>8,054,045</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>274,468</td>
</tr>
<tr>
<td>Total net assets</td>
<td>8,328,513</td>
</tr>
</tbody>
</table>

Total liabilities and net assets $ 19,952,323

STATEMENT OF ACTIVITIES

CHANGE IN NET ASSETS 12/31/14

<table>
<thead>
<tr>
<th>Support and Revenues</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Support</td>
<td></td>
</tr>
<tr>
<td>Contributions and grants</td>
<td>$ 6,514,722</td>
</tr>
<tr>
<td>In-kind contributions from the Institute for the Study of Aging, Inc.</td>
<td>2,832,504</td>
</tr>
<tr>
<td>Proceeds from special events, net of direct expenses</td>
<td>2,818,092</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Revenues</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Grant Returns</td>
<td>1,799,905</td>
</tr>
<tr>
<td>Conference registration fees and other income</td>
<td>226,173</td>
</tr>
<tr>
<td>Investment and other income</td>
<td>1,574</td>
</tr>
<tr>
<td>Foreign exchange gain</td>
<td>105,048</td>
</tr>
<tr>
<td>Total support and revenues</td>
<td>$ 14,298,018</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Program services</td>
<td>10,850,140</td>
</tr>
<tr>
<td>Fundraising</td>
<td>1,236,175</td>
</tr>
<tr>
<td>Management and general</td>
<td>493,156</td>
</tr>
<tr>
<td>Subtotal</td>
<td>$ 12,579,471</td>
</tr>
<tr>
<td>Expense for uncollected pledge</td>
<td>925,000</td>
</tr>
<tr>
<td>Total expenses</td>
<td>$ 13,504,471</td>
</tr>
</tbody>
</table>

Change in net assets | $ 793,547 |

Net assets, beginning of year | 7,534,966 |
Net assets, end of period | $ 8,328,513
RESOURCES

The Alzheimer’s Drug Discovery Foundation is committed to providing researchers with the tools they need—from research funding to connections with drug discovery experts—to further their drug discovery efforts and advance the global search for an effective treatment, and a cure. While we continue our work toward ending Alzheimer’s, the team at the ADDF is also evaluating the science behind prevention strategies to help you lower your risk.

SCIENTIFIC CONFERENCES

Our scientific conferences promote the exchange of ideas, the sharing of research results and the formulation of strategic alliances to further drug discovery and development goals. In 2014, we hosted two conferences, bringing together nearly 500 scientists, and co-sponsored and exhibited at many more. In addition to the conferences, we organized several advisory councils to identify solutions to specific challenges slowing the discovery and development of drugs to prevent and treat Alzheimer’s, shared findings from these in white papers.

alzdiscovery.org/events/conferences

ADDF ACCESS

Drug discovery is a team effort, requiring collaboration between biologists, chemists, pharmacologists and many others. In 2014, ADDF ACCESS launched an enhanced online platform to help our research community of more than 4,500 scientists connect with a virtual network of consultants and contract research organizations (CROs)—connections that are critical to advancing their drug discovery work.

addaccess.ondeckbiotech.com

PREVENTION

It’s impossible to make educated decisions about brain health without access to the scientific evidence for and against potential strategies and treatments to prevent dementia. That’s why this year our scientists launched Cognitive Vitality, a site designed to empower people to make smart, science-backed choices about brain health. The team behind Cognitive Vitality has conducted in-depth evaluations of 32 potential treatments to protect from dementia, ranging from FDA-approved drugs to natural products and supplements.

CognitiveVitality.org
“TOGETHER WE CAN CONQUER ALZHEIMER’S DISEASE”

— Leonard A. Lauder & Ronald S. Lauder, Co-Founders & Co-Chairmen, Alzheimer’s Drug Discovery Foundation